Kymera Therapeutics, Inc. · NASDAQ:KYMR
Goodman Noah sold 10,264 Kymera Therapeutics, Inc. shares (Form 4)
Traded Apr 9 to Apr 10, 2026 · Filed Apr 10, 2026
From Apr 9 to Apr 10, 2026, Goodman Noah (Chief Business Officer) sold 10,264 Kymera Therapeutics, Inc. shares at an average US$87.47 for US$898K under a trading plan, leaving 51,542 shares. Filed Apr 10, 2026 (Form 4).
- Sold
- 10,264 shares
- Price
- US$87.47 average (US$86.62 to US$89.00)
- Value
- US$898K
- Holding after
- 51,542 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Business Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Apr 9, 2026 | Common Stock | Option exercise | 2,500 | US$21.05 | 61,806 | Direct |
| Apr 9, 2026 | Common Stock | Sale | 3,094 | US$86.62 | 58,712 | Direct |
| Apr 9, 2026 | Common Stock | Sale | 2,670 | US$87.11 | 56,042 | Direct |
| Apr 9, 2026 | Common Stock | Sale | 2,500 | US$89.00 | 53,542 | Direct |
| Apr 10, 2026 | Common Stock | Sale | 2,000 | US$87.35 | 51,542 | Direct |
Source
Related
- Kymera Therapeutics, Inc.
- Goodman Noah
- Kymera Therapeutics, Inc. shareholders
- Form 4 · Goodman Noah · Jul 2, 2026
- Form 4 · Goodman Noah · Jun 25, 2026
- Form 4 · Goodman Noah · Jun 22, 2026
- Form 4 · Goodman Noah · Apr 16, 2026
- Form 4 · Mainolfi Nello · Oct 1, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Sep 8, 2026
- Form 4 · Adams Brian · Sep 4, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Atlas Venture Fund X, L.P. · Aug 13, 2026